Biolinq

company

About

Biolinq develops a wearable biosensor platform that is capable of measuring blood level information.

  • 51 - 100

Details

Last Funding Type
Series B
Last Funding Money Raised
$100M
Industries
Biotechnology,Health Care,Medical Device
Founded date
Jan 1, 2012
Number Of Employee
51 - 100
Operating Status
Active

Biolinq develops a wearable biosensor platform that is capable of measuring blood level information. Under the leadership of Jared Tangney and Josh Windmiller, Biolinq is redefining how biomedical innovations can be imagined and commercialized. While conducting his post-doctoral research at the University of California, San Diego in the laboratory for NanoBioElectronics, Josh saw the potential to bring nanotechnology to the medical world. Combining forces with Jared, a Ph.D. in Biomedical Engineering, the two saw the opportunity to bring their minimally-invasive technology to the diabetes space. Finally, people with diabetes will have a better CGM experience that is not only more affordable but also pain-free.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$100M
Biolinq has raised a total of $100M in funding over 2 rounds. Their latest funding was raised on Nov 2, 2021 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 2, 2021 Series B $100M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Biolinq is funded by 1 investors. Global Health Funds are the most recent investors.
Investor Name Lead Investor Funding Round
Global Health Funds Series B